65,437 trials
Chronic Periodontitis
Primary: Gain in Clinical Attachment Level of Periodontal Tissues — 1.361; 2.387; 1.180; 2.329 mm
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks — -1.38; -0.11 percent change of HbA1c — p=<0.001
Chronic Hepatitis C
Primary: Change From Baseline at Day 7 in log10 Hepatitis C Virus (HCV) RNA of All Participants — -2.13; -3.31; -2.91; -2.58 log10 IU/mL
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
Hepatitis C Infection
Primary: Percentage of Participants With Extended Rapid Virologic Response (eRVR) — 0; 66.7; 80.0; 55.6 percentage of participants
Hepatitis C Virus
Primary: Percentage of Participants With Extended Rapid Virologic Response (eRVR) — 18.0; 19.7; 25.7; 35.8 percentage of participants
Rheumatoid Arthritis
Primary: Number of Participants on Tocilizumab at 6 Months After Treatment Initiation — 14 participants
Solar Lentigines
Primary: Median VAS Improvement Score as Assessed by Blinded Physician Reviewers — 1.5 units on a scale — p=<0.0001
Diabetes Mellitus
Primary: Percentage of Subjects Who Reach Optimal Long-acting Insulin Dose — 88; 37 percentage of participants — p=<0.0001
Scalp Psoriasis
Primary: Percentage of Subjects With Adverse Drug Reactions (ADRs) — 3.2 percentage of participants
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
Primary: Lutenising Hormone (LH) AUC(0-8) Ratio to Baseline at Day 7 — 1.118; 0.9729; 0.8804; 0.5364 Ratio
Sporadic Amyotrophic Lateral Sclerosis
Primary: Percentage of Participants That Discontinued Study Drug — 5; 32; 5 percentage of participants
Acute Heart Failure
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs and SAEs, AEs Requiring Dose Adjustment or Interruption and…
Influenza
Primary: Number of Subjects Reporting Solicited Adverse Events (AEs) After Vaccination. — 134; 122; 74; 72 participants
Sialorrhea Secondary to Parkinson's Disease
Primary: Sialorrhea Visual Analogue Scale (VAS) — -0.55; -1.08; -1.53; -0.81 cm on VAS — p=0.6